eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer's vulnerability

Transl Lung Cancer Res. 2023 Dec 26;12(12):2570-2575. doi: 10.21037/tlcr-23-682. Epub 2023 Dec 22.

Authors

Silvia Casacuberta-Serra¹, Iñigo Gonzalez-Larreategui², Laura Soucek^{1

2

3

4}

Affiliations

¹ Peptomyc S.L., Barcelona, Spain.
² Models of Cancer Therapies Laboratory, Vall d'Hebron Institute of Oncology, Cellex Centre, Hospital University Vall d'Hebron Campus, Barcelona, Spain.
³ Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
⁴ Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Bellaterra, Spain.

No abstract available

Keywords: KRAS; MYC; Non-small cell lung cancer (NSCLC); eukaryotic initiation factor-4A (eiF4A).

Publication types

Editorial
Comment